LivaNova PLC

NASDAQ•LIVN

CEO: Mr. Alex Shvartsburg C.M.A.

セクター: Healthcare

業種: Medical - Devices

上場日: 2015-10-19

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

連絡先情報

20 Eastbourne Terrace, London, W2 6LG, United Kingdom

44-20-3325-0660

www.livanova.com

時価総額

$3.24B

PER (TTM)

-13.3

配当利回り

52週高値

$71.92

52週安値

$32.48

52週レンジ

68%

順位51Top 71.3%

3.0

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$360.86M+0.00%

直近4四半期の推移

EPS

$0.57+0.00%

直近4四半期の推移

フリーCF

$50.20M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Strong Net revenue reached $1.39B USD, increasing 10.7% versus 2024; Cardiopulmonary revenue grew 14.9% across all regions.

Segment Income Rises Cardiopulmonary segment income increased 40.9% to $108.3M USD due to revenue growth and litigation provision decrease.

Debt Obligations Reduced Total long-term debt obligations decreased 48.1% to $345.2M USD by year-end 2025 following significant repayments.

リスク要因

Global Operations Volatility Business faces risks from global market volatility, trade restrictions, fluctuating exchange rates, and supply chain challenges.

Cybersecurity Incident Risk Failure to protect IT systems or data corruption could materially affect operations, reputation, and financial condition.

Regulatory Compliance Burden Complex, evolving global regulations, including MDR and privacy laws, require significant ongoing compliance resources and costs.

Product Liability Exposure Ongoing litigation regarding 3T Heater-Cooler device poses risk of material adverse effect on financial condition and liquidity.

見通し

R&D Investment Strategy Commitment remains to developing technological enhancements, integrating AI capabilities, and pursuing new uses for existing products.

Liquidity Position Stable Current liquidity sources are deemed sufficient to fund operations over the next twelve months, optimizing capital structure as needed.

Tax Law Monitoring Company actively monitors evolving global tax legislation, including Pillar Two, to assess potential impacts on effective tax rate.

Talent Retention Focus Strategy emphasizes attracting and retaining key talent through competitive compensation, development programs, and rewarding work environment.

同業比較

売上高 (TTM)

SGRY

$3.31B

+6.2%

LIVN

$1.39B

+10.7%

PBH

$1.10B

-1.3%

粗利益率 (最新四半期)

IDYA

89.0%

+0.0pp

APLS

85.1%

+11.7pp

LIVN

66.4%

-2.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CDTX	$5.61B	-18.6	-60.1%	0.4%
XENE	$4.82B	-13.3	-55.8%	0.8%
SRRK	$4.26B	-12.7	-145.9%	26.9%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

4.4%

緩やかな成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

100%

優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月5日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし